Allogene Therapeutics Past Earnings Performance
Past criteria checks 0/6
Allogene Therapeutics's earnings have been declining at an average annual rate of -13.5%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been growing at an average rate of 11.3% per year.
Key information
-13.5%
Earnings growth rate
13.8%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 11.3% |
| Return on equity | -63.9% |
| Net Margin | -344,489.5% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Allogene Therapeutics: 2024 Platform Vision Sings Mid-Term Upside
Apr 01We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully
Mar 01
We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully
Jun 09We're Hopeful That Allogene Therapeutics (NASDAQ:ALLO) Will Use Its Cash Wisely
Feb 22Allogene Therapeutics (NASDAQ:ALLO) Is In A Good Position To Deliver On Growth Plans
Oct 27Allogene begins phase 2 allogeneic CAR T trial for large B-cell lymphoma candidate
Oct 06An Intrinsic Calculation For Allogene Therapeutics, Inc. (NASDAQ:ALLO) Suggests It's 23% Undervalued
Sep 22Allogene: Possible First Pivotal Study With Allogeneic CAR-T ALLO-501A
Sep 13Allogene Therapeutics GAAP EPS of -$0.52 beats by $0.08, revenue of $0.09M beats by $0.07M
Aug 09Companies Like Allogene Therapeutics (NASDAQ:ALLO) Are In A Position To Invest In Growth
Jul 14Allogene Therapeutics: Multibagger Potential, But Terribly Risky
Jun 24Allogene: Leading The Allogeneic CAR-T Space, Again
Apr 01Allogene: Lifting Of The Clinical Hold Will Be A Major Binary
Jan 12We're Hopeful That Allogene Therapeutics (NASDAQ:ALLO) Will Use Its Cash Wisely
Nov 05Ramifications Of Allogene's Clinical Hold: Possible Sector-Wide Implications
Oct 19Allogene Therapeutics: I Am Buying On The Clinical Hold Dip
Oct 11Revenue & Expenses BreakdownBeta
How Allogene Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -327 | 72 | 0 |
| 30 Sep 23 | 0 | -333 | 75 | 0 |
| 30 Jun 23 | 0 | -355 | 77 | 0 |
| 31 Mar 23 | 0 | -351 | 78 | 0 |
| 31 Dec 22 | 0 | -340 | 79 | 0 |
| 30 Sep 22 | 0 | -313 | 78 | 0 |
| 30 Jun 22 | 0 | -308 | 78 | 0 |
| 31 Mar 22 | 0 | -304 | 78 | 0 |
| 31 Dec 21 | 114 | -182 | 74 | 0 |
| 30 Sep 21 | 38 | -251 | 71 | 0 |
| 30 Jun 21 | 38 | -239 | 69 | 0 |
| 31 Mar 21 | 38 | -229 | 66 | -42 |
| 31 Dec 20 | 0 | -316 | 65 | 0 |
| 30 Sep 20 | 0 | -243 | 63 | 49 |
| 30 Jun 20 | 0 | -227 | 62 | 89 |
| 31 Mar 20 | 0 | -207 | 60 | 163 |
| 31 Dec 19 | 0 | -185 | 57 | 0 |
| 30 Sep 19 | 0 | -154 | 57 | 114 |
| 30 Jun 19 | 0 | -147 | 53 | 85 |
| 31 Mar 19 | 0 | -240 | 51 | 175 |
| 31 Dec 18 | 0 | -212 | 41 | 152 |
Quality Earnings: ALLO is currently unprofitable.
Growing Profit Margin: ALLO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ALLO is unprofitable, and losses have increased over the past 5 years at a rate of 13.5% per year.
Accelerating Growth: Unable to compare ALLO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ALLO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: ALLO has a negative Return on Equity (-63.89%), as it is currently unprofitable.